Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
| ▸ | USP7 | Q93009 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15167781 | 0.83 | MAPK1 (0.55) | RIPK2USP7MAPK14MAPK11MAPKAPK2 | |
| SCHEMBL10998196 | 0.82 | POLB (0.61) | RIPK2MAPK14SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2872595 | 0.81 | PTPN1 (0.50) | SMN1; SMN2NPC1RAB9AL3MBTL1NR4A3 | |
| SCHEMBL4580685 | 0.79 | ALDH1A1 (0.65) | SMN1; SMN2NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL27692438 | 0.71 | HSD11B1 (0.62) | SMN1; SMN2XDHNPC1HSP90AA1NFKB1 | |
| SCHEMBL27496860 | 0.71 | MEN1 (0.53) | SMN1; SMN2XDHNPC1HSP90AA1NFKB1 | |
| SCHEMBL10340610 | 0.71 | RIPK2 (0.64) | RIPK2MAPK14MAPK11SMN1; SMN2NPC1 | |
| SCHEMBL10624292 | 0.71 | MAPK14 (0.53) | RIPK2MAPK14SMN1; SMN2L3MBTL1NR4A3 | |
| SCHEMBL10340579 | 0.71 | RAB9A (0.50) | RIPK2SMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL10340641 | 0.71 | PTPN1 (0.50) | RIPK2SMN1; SMN2NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | claimed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| EP-2669274-B1 | TOPICAL ANTIFUNGAL AGENT | MEIJI SEIKA PHARMA CO LTD (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | RIPK2 2968/4885USP7 3498/4885MAPK14 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.